Brief: Lexicon Pharmaceuticals Completes Enrollment Of Pivotal Phase 3 Sonata-Hcm Study Of Sotagliflozin In Symptomatic Non-Obstructive And Obstructive Hypertrophic Cardiomyopathy (Hcm)
27/07/2026 13:32
BRIEF-Lexicon Pharmaceuticals Completes Enrollment Of Pivotal Phase 3 Sonata-Hcm Study Of Sotagliflozin In Symptomatic Non-Obstructive And Obstructive Hypertrophic Cardiomyopathy (Hcm) July 27 (Reuters) - Lexicon Pharmaceuticals Inc LXRX.O:
LEXICON PHARMACEUTICALS COMPLETES ENROLLMENT OF PIVOTAL PHASE 3 SONATA-HCM STUDY OF SOTAGLIFLOZIN IN SYMPTOMATIC NON-OBSTRUCTIVE AND OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM)
LEXICON PHARMACEUTICALS - TOPLINE RESULTS FOR SONATA-HCM TRIAL ANTICIPATED IN Q1 2027
Source text: ID:nGNX9WhN82
Further company coverage: LXRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lexicon Pharmaceuticals
See all newsLexicon Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Lexicon Pharmaceuticals posts Q2 net loss
Brief: Lexicon Pharmaceuticals Q2 EPS USD -0.07
Lexicon Pharmaceuticals Inc expected to post a loss of 5 cents a share - Earnings Preview
Lexicon Pharmaceuticals Inc expected to post a loss of 5 cents a share - Earnings Preview